Back to search
FDAFDA · Food and drugs·Recall number D-0008-2022

Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01.

Published October 6, 2021 · Recall initiated: September 9, 2021

Summary

FDA records drug Class I recall D-0008-2022, published October 6, 2021 and initiated September 9, 2021. Recalling firm: Jacobus Pharmaceutical Company Inc.; Status: Terminated; Reported quantity: 2,324 bottles; Lot: Lot #: 18038, 18039, Exp 03/2023; 18079, Exp 05/2023. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Jacobus Pharmaceutical Company Inc.
Distributor
Product was distributed within the USA and Canada. Control # 18038, was distributed to Canada only.
Lot
Lot #: 18038, 18039, Exp 03/2023; 18079, Exp 05/2023
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ruzurgi (amifampridine) Tablets 10 mg, packaged in 100-count bottles, Rx only, Manufactured by: Jacobus Pharmaceutical Company, Inc, P.O. Box 5290, Princeton, New Jersey 08540, NDC 49938-110-01. recalled?

Yes. FDA published recall D-0008-2022 on October 6, 2021. Reported hazard: Microbial contamination of non-sterile products: Firm's testing found lots to exceed specification for aerobic bacteria, yeast, and mold counts.

What should I do if I have this product?

Voluntary: Firm initiated · Letter